Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer [Breast Cancer]

Conclusion
Adding pictilisib to anastrozole significantly increases suppression of tumor cell proliferation in luminal B primary breast cancer.

Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Schmid, Pinder, Wheatley, Macaskill, Zammit, Hu, Price, Bundred, Hadad, Shia, Sarker, Lim, Gazinska, Woodman, Korbie, Trau, Mainwaring, Gendreau, Lackner, Derynck, Wilson, Butler, Earl, Parker, Purushotham, Thompson Tags: Combined Modality, Hormonal Therapy, Translational Oncology, Breast Cancer Source Type: research